Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Ferenci, P; Brunner, H; Laferl, H; Scherzer, TM; Maieron, A; Strasser, M; Fischer, G; Hofer, H; Bischof, M; Stauber, R; Gschwantler, M; Steindl-Munda, P; Staufer, K; Löschenberger, K; Austrian Hepatitis Study Group.
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Hepatology. 2008; 47(6): 1816-1823. Doi: 10.1002/hep.22262 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

Co-authors Med Uni Graz: Stauber Rudolf
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: We compared the efficacy and tolerability of 24 weeks of treatment with ribavirin 800 mg/day (group A) or 400 mg/day (group B) plus peginterferon alfa-2a 180 mug/week in treatment-naive patients infected with hepatitis C virus (HCV) genotype 2 or 3. A total of 97 of 141 patients randomized to group A (68.8%, 95% confidence interval [CI] 60.5%-76.3%) and 90 of 141 patients randomized to group B (63.8; 95% CI 55.3%-71.7%) achieved a sustained virological response, defined as undetectable serum HCV RNA at the end of untreated follow-up (week 48). Among patients infected with genotype 3, the rate of sustained virological response was 67.5% (95% CI 58.4%-75.6%) in group A and 63.9% (95% CI 54.7%-72.4%) in group B, and among patients infected with genotype 2, the rate of sustained virological response was 77.8% (95% CI 54.2%-93.6%) in group A and 55.6% (95% CI 38.4%-83.7%) in group B. Relapse rates in the 2 treatment groups were similar (17% in group A and 20% in group B). The incidence of adverse events, laboratory abnormalities, and dose reductions was similar in the 2 treatment groups. CONCLUSION: The results suggest that when administered for 24 weeks with peginterferon alfa-2a, ribavirin doses of 400 and 800 mg/day produce equivalent outcomes in patients infected with HCV genotype 3.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Antiviral Agents - administration and dosage; Dose-Response Relationship, Drug -; Drug Therapy, Combination -; Drug Tolerance -; Female -; Follow-Up Studies -; Genotype -; Hepacivirus - genetics; Hepatitis C - blood; Humans -; Interferon Alfa-2a - adverse effects; Male -; Middle Aged -; Polyethylene Glycols - adverse effects; Prospective Studies -; RNA, Viral - blood; Recurrence -; Ribavirin - administration and dosage; Treatment Outcome -